Navigation Links
Medarex to Present at the 26th Annual JPMorgan Healthcare Conference
Date:1/3/2008

PRINCETON, N.J., Jan. 3 /PRNewswire-FirstCall/ -- Medarex, Inc. (Nasdaq: MEDX) announced today that it is scheduled to present at the 26th Annual JPMorgan Healthcare Conference at 10:30 a.m. ET on Tuesday, January 8, 2008. The event will be webcast live and will be available in the Investor Relations section of the Medarex Web site at http://www.medarex.com. An archived edition of the presentation will be available following the event.

About Medarex

Medarex is a biopharmaceutical company focused on the discovery, development and potential commercialization of fully human antibody-based therapeutics to treat life-threatening and debilitating diseases, including cancer, inflammation, autoimmune disorders and infectious diseases. Medarex applies its UltiMAb(R) technology and product development and clinical manufacturing experience to generate, support and potentially commercialize a broad range of fully human antibody product candidates for itself and its partners. More than 30 of these therapeutic product candidates derived from Medarex technology are in human clinical testing or have had INDs submitted for such trials, with seven of the most advanced product candidates currently in Phase 3 clinical trials or the subject of regulatory applications for marketing authorization. Medarex is committed to building value by developing a diverse pipeline of antibody products to address the world's unmet healthcare needs. For more information about Medarex, visit its Web site at http://www.medarex.com.

Medarex(R), the Medarex logo and UltiMAb(R) are registered trademarks of Medarex, Inc. All rights are reserved.


'/>"/>
SOURCE Medarex, Inc.
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1

Related biology technology :

1. Medarex to Present at Thomas Weisel Partners Healthcare Conference 2007
2. Medarex to Present at the Bear Stearns 20th Annual Healthcare Conference
3. Medarex Announces Extension of Broad Antibody Development Relationship with Centocor
4. Medarex to Present at the A.G. Edwards 2nd Annual Emerging Growth Conference
5. Medarex to Present at the UBS Global Life Sciences Conference
6. Medarex Announces Election of Marc Rubin as New Board Member
7. Imagenetix Inc. to Present at Noble Small Cap Financial Conference on August 21, 2007
8. Avicena Group to Present at Noble Financial Conference
9. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
10. Strategic Diagnostics to Present at Two Upcoming Investor Conferences
11. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/17/2010)... BALTIMORE , March 17 Champions Biotechnology, Inc. (OTC Bulletin Board: CSBR), a ... the value of oncology drugs, today announced its financial results for the third  fiscal quarter ... the Company,s Form 10-Q at www.championsbiotechnology.com . , ... ...
(Date:3/17/2010)... ( AEZS, TSX: AEZ) (the "Company"), a late-stage drug development company specialized in ... and operating results before market open on Wednesday, March 24, 2010 . ... later that same day at 10:00 a.m., Eastern Time . , ... ...
(Date:3/17/2010)... ... on Stereomicroscopy and Converting to 3D Imaging , ... Thornwood, N.Y. (PRWEB) March 17, 2010 -- Carl Zeiss, ... and industrial applications, recently announced two exciting online promotions. For a limited time, and ...
(Date:3/16/2010)... 16, 2010)Pancreatic cancerknown as the most fatal cancer with ... promising approach may come in the form of tiny ... a novel procedure called "nanoembolization," said researchers at the ... Tampa, Fla. , "As current treatments for pancreatic cancer ...
Breaking Biology Technology:Champions Biotechnology Reports Fiscal 2010 Third Quarter Financial Results 2Champions Biotechnology Reports Fiscal 2010 Third Quarter Financial Results 3Champions Biotechnology Reports Fiscal 2010 Third Quarter Financial Results 4Champions Biotechnology Reports Fiscal 2010 Third Quarter Financial Results 5Champions Biotechnology Reports Fiscal 2010 Third Quarter Financial Results 6Champions Biotechnology Reports Fiscal 2010 Third Quarter Financial Results 7Champions Biotechnology Reports Fiscal 2010 Third Quarter Financial Results 8Æterna Zentaris to Announce Fourth Quarter Full Year 2009 Financial and Operating Results on March 24, 2010 2Carl Zeiss Offers Online Promotions 2Going for gold with a novel interventional radiology treatment for pancreatic cancer 2Going for gold with a novel interventional radiology treatment for pancreatic cancer 3
... Inc. (Amex: IMA ) today announced that ... Conference on Tuesday, August 12, 2008,at the InterContinental ... is scheduled to present at 4:30 pm and ... through a webcast accessible at, http://www.corporateir.net/ireye/conflobby.zhtml?ticker=IMA&item_id=1887690 , as ...
... Fiscal Year service revenue grows approximately 33% ... - Operating margin ... the ... BOSTON, Aug. 6 PAREXEL International,Corporation (Nasdaq: PRXL ) today announced its financial results for the,fourth ...
... Vista Partners announced today that,it has updated coverage ... Corporation (Amex: INO ). "The proposed merger of ... can create and deliver,therapeutic agents and positions Inovio/VGX, based ... arena as other gene therapy,companies," said Ross Silver, Director ...
Other Biology Technology:Inverness Medical Innovations to Present at Canaccord Adams 28th Annual Growth Conference on August 12, 2008 2PAREXEL Reports Fourth Quarter and Fiscal Year 2008 Financial Results 2PAREXEL Reports Fourth Quarter and Fiscal Year 2008 Financial Results 3PAREXEL Reports Fourth Quarter and Fiscal Year 2008 Financial Results 4PAREXEL Reports Fourth Quarter and Fiscal Year 2008 Financial Results 5PAREXEL Reports Fourth Quarter and Fiscal Year 2008 Financial Results 6PAREXEL Reports Fourth Quarter and Fiscal Year 2008 Financial Results 7PAREXEL Reports Fourth Quarter and Fiscal Year 2008 Financial Results 8PAREXEL Reports Fourth Quarter and Fiscal Year 2008 Financial Results 9PAREXEL Reports Fourth Quarter and Fiscal Year 2008 Financial Results 10PAREXEL Reports Fourth Quarter and Fiscal Year 2008 Financial Results 11PAREXEL Reports Fourth Quarter and Fiscal Year 2008 Financial Results 12PAREXEL Reports Fourth Quarter and Fiscal Year 2008 Financial Results 13PAREXEL Reports Fourth Quarter and Fiscal Year 2008 Financial Results 14Vista Partners Updates Coverage on Inovio Biomedical Corporation (Amex: INO); $3.57 Price Target 2
(Date:3/18/2010)... , Leafcutter ant queens can live for twenty years, fertilizing ... of sexual activity. , Danish researchers who have studied ... 1992 discovered that in both ant and bee species in ... the survival of its own sperm over the other males, ...
(Date:3/18/2010)... , Boston, Mass. -- Hemangiomas -- strawberry-like birthmarks that ... but up to 10 percent cause tissue distortion or ... the 1960s, problematic hemangiomas have been treated with corticosteroids ... side effects, don,t always work, and their mechanism of ...
(Date:3/18/2010)... University of Florida engineering researchers have found they can ... say opens the door to a wave of new technologies ... about the research appears in this week,s advance online edition ... Ben Koopman and Brij Moudgil say they used lasers not ...
Breaking Biology News(10 mins):Females shut down male-male sperm competition in leafcutter ants 2Stem cells used to model infant birth defect 2Stem cells used to model infant birth defect 3Engineers: Weak laser can ignite nanoparticles, with exciting possibilities 2Engineers: Weak laser can ignite nanoparticles, with exciting possibilities 3Largest gene study of childhood IBD identifies 5 new genes 10724 1Largest gene study of childhood IBD identifies 5 new genes 10724 2American Heart Association Late Breaking Clinical Trial Report 3A Tests Predict Which Patients Are Resistant to Anti Clotting Therapy During Angioplas 61370 1American Heart Association Late Breaking Clinical Trial Report 3A Tests Predict Which Patients Are Resistant to Anti Clotting Therapy During Angioplas 61370 2American Heart Association Late Breaking Clinical Trial Report 3A Tests Predict Which Patients Are Resistant to Anti Clotting Therapy During Angioplas 61370 3Love Hormone May Trigger Jealousy Too 61369 1Love Hormone May Trigger Jealousy Too 61369 2
... in the retail nursery industry and with many home ... a variety of plants, conserve water, and reduce the ... lined with polyethylene film on the bottom and covered ... mats help minimize evaporation while allowing water to move ...
... knot have been linked to bait use of horseshoe crabs. ... weight of red knots when they leave Delaware Bay has ... crabs, has been reduced. The study also revealed that red ... population size of red knots has declined by more than ...
... new, year-long University of Pennsylvania survey of dog owners ... pets, veterinary researchers have found that most of these ... are modified. , The study, published in the current ... showed that using non-aversive or neutral training methods such ...
Other Biology News:Capillary mats labor-saving, economical alternative to hand watering 2Decline of shorebird linked to bait use of horseshoe crabs 2If you're aggressive, your dog will be too, says veterinary study at University of Pennsylvania 2
Bovine Renal Artery Smooth Muscle Cells (BRASMC) (>500,000 cells)...
Porcine Aortic Endothelial Cells (PAOEC) (>500,000 cells)...
alpha-N-Catenin Antibody Shipping Temperature: HOT Storage Temperature: -20C...
... Light Chain MAP1A and MAP1B are microtubule-associated ... and components of the cytoskeleton. MAP1A and MAP1B ... multiple light chain subunits. The protein encoded by ... subunits and can associate with either MAP1A or ...
Biology Products: